BackEuropean Biotech Acquisition Overview

European Biotech Acquisition Other Current Liabilities

Track European Biotech Acquisition's other current liabilities ($440K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$436031.00
↓ 2.52% YoYΔ $-11264.00 vs prior year quarter

Peer average

Loading

European Biotech Acquisition Other Current Liabilities History

Loading

European Biotech Acquisition vs. peers: Other Current Liabilities Comparison

Loading

European Biotech Acquisition Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

European Biotech Acquisition (EBAC) FAQ

As of the most recent data (December 2022), EBAC shows a other current liabilities of $440K. That compares with $450K in the prior-year period — down 2.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, EBAC's other current liabilities is now $440K (was $450K) — a 2.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether European Biotech Acquisition is outperforming or lagging.

Tracking EBAC's other current liabilities over time shows whether European Biotech Acquisition is scaling, shrinking, or reshaping that part of the business. The current reading is $440K That compares with $450K in the prior-year period — down 2.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has European Biotech Acquisition's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $440K) with ownership activity and broader fundamentals.